Sistema de Salut de Catalunya
Institut Català de la Salut
[Wirth LJ] Department of Medicine, Massachusetts General Hospital, Boston, MA, USA. [Brose MS] Sidney Kimmel Cancer Center of Jefferson University Health, Philadelphia, PA, USA. [Elisei R] Endocrine Unit, Department of Clinical & Experimental Medicine, University of Pisa, Pisa, Italy. [Capdevila J] Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. IOB Quirón-Teknon, Barcelona, Spain. [Hoff AO] Department of Endocrinology, Endocrine Oncology Unit, Instituto de Cancer do Estado de Sao Paulo, Sao Paulo, Brazil. [Hu MI] Department of Endocrine Neoplasia & Hormonal Disorders, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Vall d'Hebron Barcelona Hospital Campus
2022-10-26T12:31:11Z
2022-10-26T12:31:11Z
2022-09
Medullary thyroid cancer; Selpercatinib; Targeted therapy
Cáncer medular de tiroides; Selpercatinib; Terapia dirigida
Càncer medul·lar de tiroide; Selpercatinib; Teràpia dirigida
Selpercatinib is a first-in-class, highly selective and potent, central nervous system-active RET kinase inhibitor. In the phase I/II trial, selpercatinib demonstrated clinically meaningful antitumor activity with manageable toxicity in heavily pre-treated and treatment-naive patients with RET-mutant medullary thyroid cancer (MTC). LIBRETTO-531 (NCT04211337) is a multicenter, open-label, randomized, controlled, phase III trial comparing selpercatinib to cabozantinib or vandetanib in patients with advanced/metastatic RET-mutant MTC. The primary objective is to compare progression-free survival (per RECIST 1.1) by blinded independent central review of patients with progressive, advanced, multikinase inhibitor-naive, RET-mutant MTC treated with selpercatinib versus cabozantinib or vandetanib. Key secondary objectives are to compare other efficacy outcomes (per RECIST 1.1) and tolerability of selpercatinib versus cabozantinib or vandetanib.
Article
Published version
English
Proteïnes quinases - Inhibidors - Efectes secundaris; Tiroide - Càncer - Tractament; DISEASES::Neoplasms::Neoplasms by Site::Endocrine Gland Neoplasms::Thyroid Neoplasms; Other subheadings::Other subheadings::Other subheadings::/drug therapy; CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Molecular Mechanisms of Pharmacological Action::Enzyme Inhibitors::Protein Kinase Inhibitors; Other subheadings::Other subheadings::Other subheadings::/adverse effects; ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias de las glándulas endocrinas::neoplasias de la tiroides; Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia; COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::mecanismos moleculares de acción farmacológica::inhibidores enzimáticos::inhibidores de proteínas cinasas; Otros calificadores::Otros calificadores::Otros calificadores::/efectos adversos
Future Medicine
Future Oncology;18(28)
https://doi.org/10.2217/fon-2022-0657
Attribution-NonCommercial-NoDerivatives 4.0 International
http://creativecommons.org/licenses/by-nc-nd/4.0/
